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P:10/5 - Chlamydia / Gonococd / Treponema ITuP257I Application of the Nucli5ens Basic Kit® for the
detection of Chlamydia pneumoniae
·positive by IgG Western blot (RJVM. NL).
b. All 18 VDRL pos and 16/45 VDRL neg samples were anti-TmpA pos.
Conduslon: Sensitivity of INNO-LIA8 syphilis assay seems to be higher
than the FTA, based on the positivity of the 8 samples in screening and 2
blotting tests. No specificity problems were detected. Further study is
needed to investigate the relationship between anti-TmpA re2ctivity and
2ctive di~2se.
ITuP256! Evaluation of the INNo-UA8 syphilis assay
D. Baetens·, B. Weiset, M. Van De Vyvere2,J. Scheilekens3, T.
Vervoort4, A. Mertensl
lAZ Middelheim; 2AZ Stuivenberg; 4ITG, Antwerp, Belgium; JRIVM,
Bilthoven, Netherlands
Objectives: We evaluated sensitivity and specificity of the INNO-LIA8
syphilis kit by using FTA (Trepo-Spot IF, bioMerieux) and a home made
IgG Western blot (RIVM) as reference methods. Correlation between
TmpA antibodies (Ab) and pos VORL as active disease indicator was
investigated.
Materials and methods: a. INNO-LIA8 syphilis (lnnogenetics) is a immu-
noblot assay for confirmation of pos syphilis screening results. Reactivity
against 4 T. pallidum antigens is tested (Recombinant proteins TpN47,
TpN17, TpN15 and the synthetic peptide TmpA). 135 screening pos
samples (Enzygnost® syphilis ELISA) were analyzed by INNO-LIA~.62
screening neg, FTA neg samples containing Ab known to interfere with
syphilis testing (B. burgdorferi, HIV, EBV IgM, rheumatoid factor, anti-
nuclear factor) were also tested. IgG Western blot was performed on
discrepant test results ofINNO-LIA8 and FTA. b. 18 FTA pos, VDRL
titer> 1/16 samples and 45 FTA pos, VDRL neg samples were tested on
TmpA reactivity.
Results: a.
ITuP255I Multicenter comparison trial for the detection of
Chlamydophila pneumon/ae by PCR
P. Apfaltert, F. Blasi',J. Boman3, C. Gaydos4, M. Maass5, A. Meijer6, K.
Persson', C. Y. W. Tong8, G. Stanek!, A. M. HirschIl
lDepartment ofClinical Microbiology, Hygiene-Imtitute, University of Vienna,
Austria; 2Institute ofRespiratory Diseases, University ofMilan, Italy;
JDepartment ofClinical Virology, Umed, Sweden University Hospital;
4Department ofMedicine, Division of Infectious Diseases, The Johns Hopkim
University, Baltimore, Maryland, United States; 'Institute ofMedical
Microbiology, Medical University ofLubeck, Germany; 6Research Laboratory
for Infectious Diseases, National Institute ofPublic Health and the Environment,
Bilthoven, Netherlands; 'Department ofClinical Virology, Malmo General
Hospital, University ofLund, Sweden; 8Department ofMedical Microbiology
and Genitourinary Medicine, University ofLiverpool, United Kingdom
Objective: This study was conducted to compare different DNA extraction
methods and PCR protocols for the detection of Chlamydophila (C.)
pneumoniae within atherosclerotic lesions.
Method: Identical, homogenated atherosclerotic vessel wall specimens (n =
15) and C. pneumoniae spiked controls (n = 4) as well as a negative control
were analyzed by means of16 different testing methods in 9 different centers.
Results: Positivity rates for atheroma samples varied from 0--0%.21/240
analyses (8.75%) performed on 15 atheroma samples were rated as being
positive but the maximum concordant result for positivity was only 25% for
one carotid artery sample. 09/240 analyses (91.25%) were reported as being
negative, with 4/15 (26.6%) by means ofall 16 testing methods. 3/16 (18.75)
negative controls were falsely rated positive.
Condusions: There was no consistent pattern of positive results and
reported detection rates for the atheroma samples did not correlate with
the sensitivities ofthe assays in most cases. Standardization ofPCR protocols
for the detection of C. pneumoniae is urgently needed.
fTA Positive fTA Negative
K. Loens, M. leven, D. Vrsi, H. Goossens
Dep. Medical Microbiology, University ofAntwerp, Belgium
Objectives: Chlamydia pneumoniae is an etiologic 2gent of respiratory tract
infections in humans. In the past, diagnosis ofinfection by this organism was
b2Sed on serology and culture. Nucleic acid sequence based amplification
(NASBA) might offer an alternative. The aIm ofthe study was to develop an
assay for the detection of Chlamydia pneumoniae in respiratory specimens
based on NASBA amplification and detection of a 165 rRNA target
sequence using the NucliSens Basic Kit®.
Methods: Primers and a biotin capture probe specific for the detection ofC.
pneumoniae were designed. Several commensal bacterial species and bacterial
spp causing respiratory tract infections were used to test the specificity ofthe
2ssay. A plasmid was constructed containing the wild type (WT) C.
pneumoniae 16S rRNA and the analytical sensitivity of the NucliSens Basic
Kit® based e. pneumoniae 16S rRNA primers was evaluated through testing
of dilution panels of this WT in vitro RNA.
Results: The sensitivity of the assay was determined at 10 molecules input
(WT in vitro NA). In addition, specific detection of C. pneumoniae 16S
rRNA amplicons could be achieved by the proper selection of a target
RNA-derived oligonulcleotide probe to capture the amplicons on para-
magnetic be2ds and subsequent e1ectrochemiluminescence-based detection
employing the non target RNA-derived e1ectrochernoluminescence probe
of the NucliSens Basic Kit®.
Conduslons: The NudiSens Basic Kit® could become a useful and user-
friendly diagnostic tool for the detection ofC. pneumoniae.
ITuP25S! The use ofTMA to confirm positive Chlamydia EIA
assays
D. N. Petts l , W. M.J. HiIIt, R. N. Shen2
lMicrobiology, Basildon Hospital; 2Genito-Urinary Medicine, Orsett, United
Kingdom Hospital
Objectives: To investigate the use ofTMA on samples previously processed
for EIA testing for Chlamydia trachomatis
Methods: Genital tract swabs from 193 patients attending a genito-urinary
medicine clinic were tested for the presence of C. trachomatis by EIA
(VIDAS, bioMerieux). The samples examined were 122 male urethral
swabs, and 71 cervical and urethral i swabs from females, which were
combined and treated as one specimen for examination. Tie patients were
attending for a new episode of ""re. The residue of each treated sample for
the EIA investigation was centrifuged and then re-tested by a transfer
mediated amplification (TMA) assay (Gen-Probe) for C. trachomatis
rRNA.
Results: One hundred and eighty-nine samples gave the same result for both
assays (165 negative and 24 positive), three samples were positive by the
TMA assay only and one TMA positive sample gave an equivocal result by
EIA.
Conduslons: This study showed that the Chlamydia TMA assay can be
performed on the residue of samples which have been processed for
examination by VillAS EIA, and can be used as a confirmatory test. The
three samples, which were negative by EIA, had higher relative fluorescent
index values than the other negative samples, although still below the grey
zone cut-off value. This suggests that a lower EIA threshold value could be
used to select samples for confrrmation by TMA assay.
ITuP259I Detection of Ureaplasma urealyticum in urogenital
specimens by PCR
N. Mikhailov, I. Symeschenko, P. Ogarkov, o. Kurjanovich
Military Medical Academy, St. Petersburg, Russian Federation
Objectives: 155 urogenital specimens from male patients with nongono-
coccal urethritis and 65 female patients with genital infections were exam-
ined for U. urealyticum by PCR and culture.
Methods: DNA sequenses were amplified in a tot21 volume of 50 1-'1. The
selected primers were V4 and US (Blanchud et al. 1993). Amplified
products after 42 cycles PCR (94°C for 40 sec. denaturation, annealing at
60° C for 60 sec., alongation at noc for 60 sec. and final alongation at noe
for 5 min.) were analyzed by electrophoresis through 2% agarose gel.
Product DNA W2S visu2bli2ed by UV fluorescence after ethidium bromide
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staining. for ureaplasmal culture five IO-fold dilution were made from 100
mkl aliquot of each specimen in 10 B and SP4 broths. An aliquot (20 1'1) of
each dilution was inoculated SP4 agar.
Results: Of 220 samples, 126 were initially positive by PCR, including 16
samples that were PCR-positive and culture negative and 60 that were
PCR-negative and culture-positive. 34 samples were both PCR- and
culture-negative. In the case of the 60 samples that were PCR-negative
and culture positive the lack ofsensitivity ofour assay was not a likely cause,
as some of these samples were shown by culture to contain> 10· cu/ml. To
reduce the concentration of inhibitory substances, PCR detection was
repeated an these samples with only 2 J,£1 (instead 7 1'1) added to reaction.
Of60 samples that were previously PCR-negative and culture-positive 55
were shown this time to be PCR-positive with 5 remaining negative. These
5 were shown by culture to contain < 50 cu in 250 1'1.
Conclusions: Results indicate that PCR is equal to if in not more sensitive
than culture for detection ofU. urealyticum by PCR « 24 h.) compared to
culture (3-5 days) will be particularly important in management ofpatient
with genital infections.
ITuP260IUreaplasma urealyticum serotype dlerentiation
using a newly developed EUSA method
A. Naessens, f. Echahidi, G. Muyldermans, S. Lauwers
Department ofMicrobiology, Academisch Ziekenhuis, VUB, Brussels, Belgium
Objectives: Ureaplasma urealyticum comprises 14 serotypes. Serotyping
methods, used until now, are in general time consuming, labor intensive,
very difficult to interpret and can not be performed on primary isolates. We
developed a new serotyping method based on the ELISA methodology
using serotype-specific monoclonal antibodies (MAbs) in order to enable the
typing of U. urealyticum isolates from primary broth cultures.
Methods: Broth cultures ofthe 14 serotypes of U. urealyticum were used for
the antigen preparation. Antigens were diluted in ethanol and used for
coating polysorp-Nunc plates. After a blocking step, MAbs were added,
followed by the addition ofthe anti-mouse-immunoglobulins conjugated to
horseradish peroxidase. Absorbency was measured after the addition of a
chromogenic substrate.
Results: Each of the 14 serotype reference strains tested against the 14
selected MAbs showed a strong reaction with its homologous MAb.
Cross-reactions observed were MAb-5 with serotype 2, MAb-14 with
serotype 3 and MAb-8 with serotype 13. No significant inter run variation
of a stored antigen preparation was found. However, inter run variation of
different antigenic preparations was considerable. Nevertheless, homolo-
gous reactions were always very prominent as compared to negative
controls. Despite the crossreactions observed, all the serotypes of U.
urealyticum could be identified and differentiated using a combination of
the MAbs described.
Conclusions: Our newly developed ELISA seems promising for serotyping
U. urealyticum clinical isolates.
ITuP261I Development of monoclonal antibodies against
Ureaplasma urea/ytlcum serotypes and their use for serotyplng
dinical isolates
f. Echahidi, G. Muyldermans, S. Lauwers, A. Naessens
DepartlfU'nt ofMicrobiology, Academisch Ziekenhuis, VUB, Brussels, Belgium
Objectives: Ureaplasma. urealyticum comprises 14 serotypes. Until now,
serotyping studies have been performed with polyclonal antibodies
(PAbs). However, the use of PAbs for serotyping raised problems such as
polyreactivity in clinical isolates and lack ofreproducibility. As alternative to
PAbs, we started the development ofmonoclonal antibodies (MAbs) against
serotypes 2,5,7,8, 10, II, 12, and 13 (serotypes for which no MAbs were
available).
Methods: Antigenic preparations of serotypes 2, 5, 7, 8, 10, 11, 12 and 13
reference strains were used for Balblc mice immunisation. Lymphocytes
from immunised mice were fused with NSO mouse myeloma cell line.
Positive clones producing specific antibodies were screened by colony-
immunofluorescence assay (IFA). Evaluation of MAbs for scrotyping in
comparison to PAbs was performed by serotyping 21 selected clinical
isolates by colony-IFA.
Results: MAbs against serotypes 2, 5, 7, 8,10, II, 12 and 13 were developed.
Although some cross-reactions were observed, all the serotypes of U.
urealytiCNm could be identified and differentiated using a combination of
the complete set of MAbs. MAbs were able to identify 18 out of the 21
clinical isolates. Polyreactivity, which occurred in 19 out of the 21 isolates
with PAbs, was not observed with MAbs.
Conclusions: MAbs seem to be a morc valuable tool than PAbs for
serotyping U. urealyticum.
ITuP262! Evaluation of the V1DAS PROBE Chlamydia
trachomatis Test
R.]ohnson l , A. Hem2, A. Traverse2, P. Wells2, K. Kacena2, M.
Longiaru1, S. Kuchimanchi2, D. Keys2
'Cen-Probe, San Diego CA; 2bioMerieux, Rockland, MA, United States
Objectives: To evaluate the VlDAS PROBE Chlamydia trachomatis (CT)
Test using pre-clinic21 swab and urine specimens.
Methods: The VIDAS PROBE Chlamydia trachomatis Test is an 2uto-
mated assay employing Transcription-Mediated Amplification (TMA) of
CT ribosomal RNA (rRNA). Both amplification and detection of the
amplified target occur in the VIDAS PROBE strip, a disposable unit-dose
format. The test is initiated by adding processed specimens to the VIDAS
PROBE strip. The strip is then placed in the VIDAS AMPstation instrument
where co-amplification of both target and an internal control occur. The
internal control monitors for amplification failure in each individual sample
and control. Amplified products are detected on the VIDAS system using
solid-phase capture of the amplified product and generation ofa fluorescent
product.
Results: 146 endocervical swabs, 100 urethral swabs, 181 female urine
specimens and 96 male urine specimens with known culture results were
evaluated at bioMerieux. Discrepant results were resolved using another
amplified test (Gen-Probe AMPLIFIED CT or Abbott LeX). Resolved
sensitivity and specificity for endocervical swabs and male and female urines
was 100%. Sensitivity was 100% and specificity 99% with urethral swabs.
Invalid results, as monitored by internal control amplification, were
observed in 1% offemale urine specimens and 0% ofmale urine specimens.
Condusions: The VIDAS PROBE Chlamydia trachomatis Test, co-devel-
oped by Gen-Probe and bioMerieux, provides a sensitive and specific
automated assay for the detection ofCT in a convenient unit-dose format.
ITuP263I Comparing VIDAS PROBE crand GEN-PROBE
AMPUFIED cr for detecting Chlamydia trachomatis
A. Hem!, K. Kacena!, A. Traverse!, P. Wells!, R.]ohnson2,J. Connolly!,
M. Longiaru2• G. McKinley!, D. Keys!
'bioMerieux, Rockland, MA; 2Cen-Probe, San Diego, CA, United States
Objectives: To comp2re the performance of the Gen-Probe AMPLIFIED
Chlamydia trachomatis (CT) assay and the VIDAS PROBE CT Test using
pre-clinical swab and urine specimens.
Methods: The Gen-Probe AMPLIFIED CT assay and the VIDAS PROBE
CT Test both employ Transcription-Mediated Amplification (TMA) ofCT
ribosomal RNA (rRNA). For VIDAS PROBE CT processed specimens
were added to the VIDAS PROBE strip, a disposable unit-dose format,
amplified on the automated VIDAS AMPstation and detected on the
VIDAS instrument. For AMPLIFIED CT, rRNA from processed specimens
was amplified in a water bath and detected by chemiluminescence on the
Gen-Probe LEADER instrument. Discrepant results were resolved using
Abbott LcX and culture data.
Results: 64 endocervical swabs, 85 urethral swabs, 129 female urine speci-
mens and 51 male urine specimens were evaluated at bioMerieux. After
adjudication ofdiscrepant results, VIDAS PROBE CT and AMPLIFED CT
sensitivity was 100% for endocervical and urethral swabs. For female urine
specimens, sensitivity was 100% with the VIDAS PROBE CT Test and
89% with the AMPLIFIED CT assay. For male urine specimens sensitivity
was 100% with the VIDAS PROBE CT assay and 94% with the AMPLI-
FIED CT assay. Specificity was !OO% for both a..ays with endocervical
swabs and male and female urine specimens. For urethral swabs, specificity
was 96% with the VIDAS PROBE CT Test and 100% with the AMPLI-
FIED CT assay.
Conclusions: In this ongoing preclinical study, VlDAS PROBE CT Test
and AMPLIFIED CT had equivalent sensitivity and specificity.
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ITuP264IPerformance of the new Gen-Probe APTIMA™
Combo 2 assay in detecting Chlamydia trachomatis and
Neisseria gonorrhoeae from endocervical and urine specimens
In women
D. V. Ferrerol , D. H. Martinz, D. E. Schultzl , C. CammarataZ
'San Joaquin County Public Health Services, Stockton CA; 2LSU Medical
Center, New Orleans LA, United States
Objective: We evaluated a new generation Transcription-Mediated Ampli-
fication (TMA) assay (Gen-Probe) that incorporates target capture in a dual
kinetic chemiluminescent detection system for detecting Chlamydia tracho-
matis (CT) and Neisseria gono"hoeae (GC) from swabs and first catch urine
(FCU).
Methods: Four endocervical swabs and one FCU specimen were colleered
from 205 female STD clinic patients. From every patient, the same urine
specimen was used for each assay. Swab and FCU specimens were tested by
the APTIMA Combo 2 (Combo), ligase chain reaction (LCR), and poly-
merase chain reaction (PCR) assays for CT. Swab s~cimens were tested by
Combo, LCR and culture for GC. FCU specimens for GC were tested by
Combo and LCR.
Results: In comparison to LCR, Combo CT swab sensitivity was 96.7%
(29{30) and Combo had a s~cificity of98.3% (169{172), while GC swab
sensitivity was 92.8% (13{14) and s~cificity was 98.9% (188{19O). When
compared to LCR, Combo CT FCU sensitivity was 95.3% (20{21) and
s~cificitywas 94.6% (174{184), while GC FCU sensitivity was 85.7% (12{
14) and specificity was 98.9% (186{188).ln comparison to PCR, Combo CT
swab sensitivity was 90.0% (27{30) and specificity was 97.1 % (170{175) and
for CT FCU, sensitivity was 94.7% (18{19) and specificity was 94.9% (166{
175). In comparison to GC culture, Combo GC swab sensitivity was 100%
(15{15) and specificity was 100% (189{189). Ofthe 27 CT Combo positive{
comparator assay negative results, 25 were positive by a TMA alternate
amplification assay.
Condusion: These results indicate good performance for the APTIMA8
Combo 2 assay.
ITuP26SI Evaluation of the VIDAS PROBE Neisseria
gononfJoeae Test
E. Burresl , M. Gilkert l , P. Hodge!, R.Johnson!, T. WangZ, D. Keysz
'Cen.Probe, San Diego, CA; 2bioMbieux, Rockland MA, United States
Objectives: To evaluate the VIDAS PROBE Neisseria gonorrhoeae (NG)
Test using pre-clinical swab and urine specimens.
Methods: The VIDAS PROBE NG Test is an automated assay in which
Transcription-Mediated Amplification (TMA) of NG ribosomal RNA
(rRNA) and amplified produer detection occur in a VIDAS PROBE
strip. The strip contains ready-to-use reagents in a disposable, unit dose
format. An internal control co-amplifies in the same strip well as the sample
and monitors amplification failure (invalid results) for each individual
sample. The test strip also includes a decontamination reagent which
inactivates the amplicon after completion of the assay.
Results: 253 endocervical swabs, 206 male urethral swabs, and 115 female
and 116 male urines with known NG culture results were tested at Gen-
Probe using the VIDAS PROBE NG Test. Following resolution, sensitivity
and specificity for both the endocervical and urethral swabs was 100%.
Invalid results were seen in 1.2% ofthe endocervical and 0.7% ofthe urethral
swabs. Sensitivity was 100% and specificity 98.9% in both female and male
urines. Invalid results were detected in 7.8% of the female and 2.6% of the
male urines. In addition, a specificity panel of 17 Australian non-NG
Neisseria clinical isolates did not cross-react in the assay.
Condusions: The VIDAS PROBE Neisseria gonorrhoeae Test, co-devel-
oped by Gen-Probe and bioMerieux, is a sensitive, specific method for the
direer identification of N. gonorrhoeae. The internal control monitors the
validity ofeach amplification reaction, and the enclosed strip and on-board
amplicon inactivation offer contamination safeguards for the clinicallabora-
tory.
ITuP266I Combine use of synthetic and recombinant antigens
7i'eponema pallidum in enzyme Immunoassay
V. Verbov, A. Ivanov, R. Chumak, A. Kolobov, G. Raevskaja
Paster Institute, S .•Petersburg, Russian Federation
Objectives: The main purpose of this work was to study some indexes of
specificity and sensitivity of synthetic and recombinant antigens Treponema
pallidum in enzyme immunoassay. Synthetic ~ptids imitating epitops of
syphilis antigen TppI7 (sif-21), Tpp41 (sif-3, sif-B) as well as recombinant
antigens Tpp17, Tpp41, Tpp47 have been studied.
Methods: Wells produced by "Costar" were used for immunosorhent
creation. As to detection of antigen-antibody complex we used peroxydase
conjugate (on the base of monoclonal antibodies to light chains of immu-
noglobulins) due to its ability to reveal total antibodies. 296 sera of patients
suffering from different forms ofsyphilis were examined to study indexes of
sensitivity (154 patients with primary syphilis, 85 - with secondary one and
57 - with latent form of infection). For detecting specificity we used 100
donors' sera, 42 sera ofpatients suffering from leptospirosis, 50 from patients
with Lyme borreliosis, 39 - from patients with different autoimmune
diseases, 59 sera from patients performing false positive reactions in cardi-
olypin tests.
Results: The total sensitivity for antigens was revealed "s the following: Sif-
21 - 98.0%, Sif-3 -98.6%, Sif-13 - 97.0%, Tpp17 - 98.6%, Tpp41 - 97.6%,
Tpp47 - 97.2%. Specificity indexes obtained were: Sif-21 - 81.7%. Sif-3-
80.0%, Sif-13 - 94.8%, Tppt7 - 94.8%, Tpp41 - 87.5%, Tpp47 - 89.3%.
Conclusions: For diagnostics of syphilis the authors can offer enzyme
immunoassay test system made on the base of combination of synthetic
antigen Tpp41 (Sif-13) and recombinant antigen Tpp17 as the most sensitive
and specific one.
ITuP267! Detection of male. symptomatic and asymptomatic.
genital Chlamydia and Neisseria Infection
C. Pina Vazl .Z, C. Lisboa3, A. Rodriguesl , A. Pintol , R. Costi, F.
Cottaz.]. Mesquita-Guimaraes3
I Department ofMicrobiology, School ofMedicine Porto; 2Department of
Microbiology; JDepartment ofDermatology and Venereology, Hospital S.Joao,
Porto, Portugal
Objective: To evaluate the polymerase chain reaction (PCR) Amplieor
Chlamydia and Neisseriae test (Roche) as compared to the VIDAS enzyme
immunoassay (BioMerieux) in diagnosing male urogenital ehlamydial and
Neisseria gono"hoeae infections.
Methods: Two urethral swabs and urine specimens were collected from 130
men attending one Sexually Transmitted Disease (SID) Clinic in Oporto,
Portugal. 53 men h"d symptomatic urethritis and 57 had no urethral
symptoms but had signs{symptoms ofother sexually transmitted infection.
The urethral swabs and the voided urine s~cimens were processed and
tested by VIDAS EtA and by Amplicor peR assay. Both positive: and
discrepant results were submitted to repeated testing and were also analysed
by Strand Displacement (SDS-Deckton-Dickinson). Both samples were also
cultured for N. gono"hoeae.
Results: The prevalences found were 6.9% (3.8% in asymptomatic patients)
for C. trachomatis and 17.7% (4.6% in asymptomatic patients) for N.
gonorrhoeae. Comparing the results of each test individually with an
improved gold standard (PCR + SDS) for the detection of C. trachomatis
and N. gono"hoeae, and after calculating the positive and negative predictive
values we found, for both microbial agents, PCR to be the highest sensitive
both with swabs and urine specimens.
Conclusions: We found a high prevalence of both agents in symptomatic
and asymptomatic patients. PCR should be the first diagnostic tool in
combined genital screening, due to higher sensitivity comparing to antigen
detection, and non invasiveness in urine samples, leading to increased patient
compliance for diagnostic testing and possibly treatment.
!TuP268I Dlerences In the antibodies responses against
antigens from Chlamydia pneumoniae
M. S. Garcia-Valdivia,]. Lopez-Barba,]. Casas-Ciria, M. A. Rodriguez-
Iglesias
Laboratory ofMicrobiology, Puerto Real University Hospital, University of
Cadiz, Spain
Objectives: To compare the antibody response to generic Chlamydia-LPS
and the s~cifie response to purified elementary bodies (EB) of Chlamydia
pneumoniae using ELISA techniques.
Methods: Eighty-three sera from patients with acute respiratory syndrome
compatible with Chlamydia pneumoniae infection were studied. All sera were
tested for detection of IgM antibodies by two ELISA techniques that ming
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ITuP269! A new treponemal test for detection Treponema
antibodies
different antigens: a) generic Chlamydia-LPS (Medac), and b) specific
Chlamydia pneumoniae-EB (Sero-CP, Savyon). Anti-Chlamydia pneumoniae
IgG antibodies was detected by indirect immunofluorescent method (MRL
Diagnostics). Statistical analysis was done using McNemar test to evaluate
both ELISA.
Results: Two sera were IgM positive against LPS and EB ELISA and 67
were negative. Disagreement results was showed in 14 sera (8 LPS positive
and 6 EB positive). According to McNemar test the z value was 0.52 (P =
0.29) that indicates a similar results in ELISA. The detection ofIgM anti-LPS
is more frequent in sara with specific anti-Chlamydia pneumoniae IgG
antibodies that IgM anti-EB (4 vs 1).
Conclusions: LPS and EB ELISA were useful for the detection of anti-
Chlamydia IgM antibodies. However the response to anti-LPS is maintained
a long time and is possible to detect IgM when is growing the IgG response.
This fact is interesting because permits to recognize recent infections and
could be detect a reactivation of chlamidial infection.
M. Garau, A. GonzaIez-Escalada, P. Alvarez, M. F. Serrano, A. Fuertes
Hospital Universitario 12 de Octubre, Madrid, Spain
ObJectives: To evaluate a new Treponema assay (Copalis®: Coupled Particle
Light Scattering) for diagnosing infections caused by Treponema palUdum.
Methods: During a period of 6 months, 1431 patients were studied to
discharge T. pallidum infection using an enzymeimmunoassay (EIA) (Captia
Select Syph-G, biotech). Serum samples from 64 patients and cerebrospinal
fluid specimens from 5 patients showed reactivity: 56 positive and 13
indeterminate (index: 0.9-1.1). All the samples which had been positive
and indeterminate by EIA were tested by Copalis (Copalis® Treponema
Antibody Test, DiaSorin Inc.) and Western-blot (WB) (T. pallidum Ig G
Marblot Strip Test System, MarDx Diagnostics). WB was considered as the
"gold standard".
Results: Out of 69 samples tested, 52 were positive by WB. These 52
specimens were also positive by Copalis (Sensitiviry: 100%) but 9 negative
samples by WB were positive by Copalis (Specificity: 65%). The positive
predictive value (PPV) and the negative predictive value (NPV) were 85%
and 100% respectively.
EIA COPALlS+ COPALlS- WB+ WB-
failed to detect 4 cases of mixed infections. As compared to the microscopy
the performance of both the assays to diagnose P.fakiparum infection was
comparable, the sensitivity for the PfHRP-2 assay was 82% with a
specificity of 99% and for the pLDH assay the sensitivity was 89% with a
specificity of99.5%. The sensitivity ofboth the assays dropped significantly
at parasitemias < 100/JLL. The PfHRP-2 assay detected 4 false positive cases,
2 of which were also detected by the pLDH assay; these patients reported
treatment with chloroquine in the last 2-5 weeks.
Conclusion: Though the immunocapture diagnostic assays may be helpful
in certain situations, however. microscopy of thick blood film is still the
method ofchoice in diagnosing imported malaria.
ITuP271I Plasmodium falciparum histidine rich protein 2
(PfHRP·2)-based immunocapture diagnostic assay for malaria:
Crossreactivity with rheumatoid factors
J. Iqbal, A. SherI
Department ofMicrobiology, Faculty ofMedicine, Kuwait University; 1Malaria
Laboratory, Ministry ofHealth, Kuwait, Kuwait
Background: Evaluation of two recently introduced rapid nonmicroscopic
immunocapture assays for the diagnosis of malaria infection for their
sensitivity and specificity.
Method: A Plasmodiumfalciparum histidine rich protein-2 (PtHRP-2) based
assay (ICT) and a Plasmodium specific lactate dehydrogenase test (OptiMAL)
were evaluated for their specificities in different groups ofpatients who were
tested negativc for malaria infection by microscopy. The patients were
selected from different disease groups: rheumatoid arthritis, hepatitis C,
toxoplasmosis, schistosomiasis and hydatid disease.
Results: 133 of the 225 patients were positive for rheumatoid factor. 35 of
the 133 (26%) rheumatoid factor positive patients gave false positive reaction
with the ICT assay but only 4 of these gave false positive reactions with the
OptiMAL test. 33 of the 35 false positive specimens became negative when
repeat tested with the ICT assay after absorbing out rheumatoid factor
activity.
Conclusion: Our study shows that the PfHRP-2 based ICT assay gives false
positive reaction in 26% of the patients who had rheumatoid factors but
were negative for malaria by microscopy.
Positive Cn = 56)
Indctermin"te (n = 13)
51
10
5
3
44
8
12
5
Conclusions: We conclude that the test's sensitivity. simplicity and speed
may make it as an important tool in the screening of Treponema infection.
However, due to the low specificity showed (65%) we recommended the
use of confirmatory tests.
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!TuP2701 Diagnosis of imported malaria by Plasmodium
lactate dehydrogenase (PLDH) and histidine rich protein 2
(pfHRP·2)-based immunocapture assays in Kuwait
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Introduction: This study was conducted to evaluate the performance oftwo
rapid non-microscopic assays, Plasmodium lactate dehydrogenase (pLDH)
assay (OptiMAL) and Plasmodium falciparum histidine rich protein 2
(PfHRP-2) assay (ICT Malaria).
Methods: The assays were used to detect malaria infection in 515 immi-
grants living in Kuwait. The performance of both the assays was compared
to that ofmicroscopy ofGiemsa stained thick blood films and to each other.
Results: Ofthe 515 patients tested, 163 were positive for malaria parasites by
microscopy ofthick blood film: 87 were infected with P. vivax parasites, 63
with P. falciparum, 1 with P. malariae and 12 had mixed infections of P.
falciparum and P. vivax. The PtHRP-2 assay detected 53 P. falciparum
infections and, as expected, it failed to detect all but one case of P. vivax.
The pLDH assay detected 56 P.falciparum cases and 77 P. "i"ax infections but
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Visceral leishmaniasis is an important infection with 8% morbidity and case
fatality rate of4% in our clinic. An early diagnosis, playa crucial role in the
decrease of mortality and complete patient recovery.
Objective: to show the significance of serologic examination parallel to
bone morrow aspiration, as an easy and rapid diagnostic method.
Materials and Methods: A direct agglutination test was used to determine
the antibodies against leishmania. 50 children (30 males and 20 females) with
visceral leishmaniasis admitted to the pediatric clinic ofinfectious diseases of
University Hospital Center ofTirana, were included in the study. The mean
patients age was 2.55 years with a range 6 months to 12 years. Forty healthy
household contacts and 30 children with other infections aged from 0.5 to 12
years (mean age 2.56) were considered as control group. The diagnosis of
control group patients was 17 cases with respiratory tract infections and 13
with gastrointestinal infections.
Results: High antibody titer against leishmania (up that 1/3200) was found
in 49 (98%) patients with the disease, while bone morrow aspiration resulted
positive in 46 (92%) cases. Antibody titer higher than 1/100000 remained at
least 3 months after recovery. The serologic examination revealed negative
results for all of control group patients (mean value 1/1600, P < 0.00(1).
The diagnostic significance ofthe method was shown by the sensitivity of
98%, specificity 100%. positive predictive value 100% and negative pre-
dictive value 98%.
Conclusion: DAT is an efficacious non invasive method in diagnosis of
visceral leishmaniasis.
